The year 2025 proved a period of profound reflection and significant change, as the world bid farewell to several influential ...
In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (4 of 4 patients) and a 100% disease control rate, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback